

Umecrine Mood AB First in class relief for premenstrual symptoms

Brief Company Description

Umecrine Mood, active in the fields of Women's Health and Psychiatry, offers a first-in-class compound for the treatment of PMDD and severe PMS. This non-hormonal, selective GABA-steroid inhibitor, in clinical development, is designed to relieve CNS symptoms such as premenstrual depression and anxiety, occurring in more than 15% of the female fertile population.

Company Description

Umecrine Mood, active in the fields of Women's Health and CNS/Psychiatry, develops first-in-class compounds for the treatment of premenstrual dysphoric disorder (PMDD) and severe premenstrual syndrome PMS. The first selected candidate drug is a non-hormonal, selective GABA-A receptor modulator, designed to relieve CNS symptoms such as premenstrual depression and anxiety. Its ability to inhibit GABA-steroid action has so far been demonstrated clinically in a phase I biomarker study in healthy women.

Women are to a greater degree than men affected by disorders such as depression. One mechanism, instrumental in the progression of these disorders, is the impairing of the GABA system leading to illness related to the menstrual cycle. PMDD, prevalent in 3-8% of women in fertile age, results in large impairment of the affected woman's quality of life and her surrounding. PMDD is also a great cost for the society in that the women are unable to work during the week prior to menstruation.

Present treatment alternatives are anti-depressants and/or oral contraceptives but their efficacy is moderate and the treatment often not well tolerated by these patients. Umecrine Mood offers a novel approach to alleviate premenstrual mental and physical symptoms, caused by the endogenous CNS-active steroids derived from the corpus luteum of the ovary. The company strategy is to take the development as far as to the demonstration of proof-of-concept for the treatment of PMDD, and with this as a basis seek a strategic partnership or a M&A transaction, with a company searching for a new opportunity within the field of Women's Health or CNS.

Umecrine Mood offers a first-in-class compound for the treatment of PMDD and severe PMS. This non-hormonal, selective GABA-steroid modulator, in clinical development, is designed to relieve premenstrual CNS symptoms, occurring in more than 15% of the fertile female population.

Intellectual Property Status

Patents protect the intellectual property of Umecrine Mood, which are based on a unique concept including compounds that can block the effect of GABA steroids on the GABA-A receptor, thus preventing the steroids from inducing negative CNS-symptoms and disorders. The lead compound, UC1010 has patents approved in all the major markets.